Relay Therapeutics (RLAY) News Today

Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 3.8% Following Analyst Downgrade

Barclays dropped their price objective on shares of Relay Therapeutics from $15.00 to $14.00 and set an "overweight" rating for the company in a report on Friday.

Relay Therapeutics (NASDAQ:RLAY) Trading 6.7% Higher

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has earned an average recommendation of "Buy" from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-mont

Relay Therapeutics (NASDAQ:RLAY) Shares Down 3.1% After Analyst Downgrade

JMP Securities lowered their price objective on shares of Relay Therapeutics from $24.00 to $21.00 and set a "market outperform" rating on the stock in a report on Thursday.

Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Analyst Downgrade

HC Wainwright decreased their price objective on shares of Relay Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday.

Relay Therapeutics (NASDAQ:RLAY) Shares Gap Up to $8.27

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 8,050,000 shares, a drop of 18.3% from the June 15th total of 9,850,000 shares. Based on an average trading volume of 1,320,000 shares, the short-interest ratio is presently 6.1 days.

Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 9.9%

Relay Therapeutics (NASDAQ:RLAY) Shares Down 4.8% Following Insider Selling

Relay Therapeutics (NASDAQ:RLAY) Shares Down 3.4%

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have been given a consensus recommendation of "Buy" by the seven analysts that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price a

Relay Therapeutics (NASDAQ:RLAY) Shares Down 4.7%

Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 5.8%

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) was the target of a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 9,600,000 shares, a decrease of 19.3% from the May 15th total of 11,890,000 shares. Based on an average trading volume of 1,310,000 shares, the days-to-cover ratio is currently 7.3 days.

BVF Inc. IL increased its position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 67.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,970,045 shares of the company's stock after buying an additional 1,6

Caxton Associates LP lifted its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 637.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 279,101 shares of the company's stock after acquiring an additional

Bellevue Group AG grew its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 21.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 5,936,082 shares of the company's stock after buying an additional 1,051,082 shares during the period. Bel

Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - HC Wainwright issued their FY2025 earnings estimates for shares of Relay Therapeutics in a report issued on Friday, June 7th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($3.10) for the year. HC Wai

HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Relay Therapeutics in a research note on Friday.

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Peter Rahmer sold 19,864 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $6.47, for a total transaction of $128,520.08. Following the transaction, the insider now owns 493,470 shares in the company, valued at $3,192,750.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Affinity Asset Advisors LLC acquired a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 300,000 shares of the company's

Rhenman & Partners Asset Management AB grew its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 105.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 390,000 shares of the company's stoc

Finepoint Capital LP boosted its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 51.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,317,870 shares of the company's stock after purchasing an additional 447,

Relay Therapeutics (NASDAQ:RLAY) Trading 11.9% Higher

Norges Bank acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 3,068,973 shares of the company's stock, valued at approximately $33,789,000. Norges Bank owned approximately

Charles Schwab Investment Management Inc. lifted its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 22.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 877,813 s

Relay Therapeutics (NASDAQ:RLAY) Shares Down 6.5%

Relay Therapeutics (NASDAQ:RLAY) Trading Up 5.3%

Relay Therapeutics (NASDAQ:RLAY) Shares Down 2.7%

Barclays raised Relay Therapeutics from an "equal weight" rating to an "overweight" rating and set a $15.00 price objective for the company in a report on Friday.